Prima BioMed (NASDAQ:IMMP) Stock Rating Lowered by Wall Street Zen

Prima BioMed (NASDAQ:IMMP) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Prima BioMed in a research note on Monday, December 15th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Prima BioMed currently has a consensus rating of “Sell”.

Prima BioMed Stock Performance

Prima BioMed stock opened at $2.76 on Friday. Prima BioMed has a 12-month low of $1.32 and a 12-month high of $3.53. The firm has a 50-day moving average price of $2.02 and a 200-day moving average price of $1.83.

Institutional Investors Weigh In On Prima BioMed

An institutional investor recently raised its position in Prima BioMed stock. Jane Street Group LLC grew its stake in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,574 shares of the biotechnology company’s stock after acquiring an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent reporting period. 2.32% of the stock is owned by institutional investors and hedge funds.

About Prima BioMed

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.